Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. (Q51064514)

28 March 2018

title

Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non-muscle-invasive bladder cancer. (English)

1 reference

28 March 2018

author

Roy Mano

1

1 reference

28 March 2018

author name string

Jack Baniel

2

1 reference

28 March 2018

Ohad Shoshany

3

1 reference

28 March 2018

David Margel

4

1 reference

28 March 2018

Tomer Bar-On

5

1 reference

28 March 2018

Ofer Nativ

6

1 reference

28 March 2018

Jacob Rubinstein

7

1 reference

28 March 2018

Sarel Halachmi

8

1 reference

28 March 2018

publication date

21 July 2014

1 reference

28 March 2018

published in

Urologic Oncology

1 reference

28 March 2018

volume

33

1 reference

28 March 2018

issue

2

1 reference

28 March 2018

page(s)

67.e1-7

1 reference

28 March 2018

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Prognostic markers for urothelial cancer: obstacles and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Prognostic role of NLR in urinary cancers: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Pretreatment parameters obtained from peripheral blood sample predicts invasiveness of bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Importance of the neutrophil-to-lymphocyte ratio in muscle-invasive and non-muscle invasive bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

NLR is predictive of upstaging at the time of radical cystectomy for patients with urothelial carcinoma of the bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Subclassification of upper urinary tract urothelial carcinoma by the neutrophil-to-lymphocyte ratio (NLR) improves prediction of oncological outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

Biomarkers in cancer staging, prognosis and treatment selection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.06.010

10.1016/J.UROLONC.2014.06.010

7 January 2021

Identifiers

DOI

1 reference

28 March 2018

PubMed ID

25060672

1 reference

28 March 2018